|
Emetogenisity
|
Index of anti-emetic guideline
|
Regimen
|
Number
|
|---|
|
Minimal (n = 7)
|
Early; (−), Delayed; (−)
|
Tmab + VNR
|
2
|
|
Tmab
|
2
|
|
VNR
|
1
|
|
MTX + VCR + PSL
|
1
|
|
temsirolimus
|
1
|
|
Low (n = 38)
|
Early; DEX, Delayed; (−)
|
GEM
|
8
|
|
S-1 + GEM
|
1
|
|
nab-PTX + GEM
|
1
|
|
nab-PTX
|
3
|
|
Tmab + PTX
|
2
|
|
PTX
|
1
|
|
DTX + S-1
|
2
|
|
DTX + EMP
|
1
|
|
DTX + PSL
|
4
|
|
DTX
|
9
|
|
eribulin
|
1
|
|
Bmab + sLV5FU2
|
1
|
|
sLV5FU2
|
3
|
|
VTD
|
1
|
|
Moderate (n = 17)
|
Early; NK1RA + 5-HT3RA + DEX, or 5-HT3RA + DEX, Delayed; NK1RA + 5-HT3RA + DEX, or 5-HT3RA + DEX
|
Bmab + CBDCA + PTX
|
3
|
|
Pmab + FOLFOX6
|
2
|
|
Bmab + CapeOX
|
1
|
|
CapeOX
|
3
|
|
SOX
|
1
|
|
Bmab + FOLFIRI
|
1
|
|
Bmab + IRIS
|
1
|
|
IRIS
|
2
|
|
CPT-11
|
2
|
|
VCD
|
1
|
|
High (n = 11)
|
Early; NK1RA + 5-HT3RA + DEX, Delayed; NK1RA + 5-HT3RA + DEX
|
CDDP + CPT-11
|
4
|
|
FEC
|
2
|
|
EC
|
2
|
|
R-CHOP
|
3
|
- Tmab; Trastuzumab, VNR; vinorelbine, MTX; Methotrexate, VCR; Vincristine, PSL; Prednisolone, GEM; Gemcitabine, nab-PTX; nab-Paclitaxel, DTX; Docetaxel, EMP; estramustine, Bmab; Bevacizumab, sLV5FU2; simplified biweekly 5-FU & leucovorin, VTD; bortezomib, thalidomide, dexamethasone, CBDCA; Carboplatin, FOLFOX6; combination of Oxaliplatin and 5FU, CapeOX; capecitabine plus intermittent oxaliplatin, SOX; S-1 plus intermittent oxaliplatin, FOLFIRI; combination of Irinotecan and 5FU IRIS; CPT-11; Irinotecan, VCD; bortezomib, Cyclophosphamide, dexamethasone, CDDP; Cisplatin, FEC; 5FU, Epirubicin, Cyclophosphamide, EC; Epirubicin, Cyclophosphamide, R-CHOP; Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.
